Lonza Group AG (LZAGF)
USD 588.7
(0.0%)
USD 588.7
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 880 Million CHF | -44.58% |
| 2022 | 1.54 Billion CHF | 81.08% |
| 2021 | 851 Million CHF | -5.55% |
| 2020 | 901 Million CHF | -7.3% |
| 2019 | 972 Million CHF | 15.44% |
| 2018 | 842 Million CHF | 16.46% |
| 2017 | 723 Million CHF | 48.77% |
| 2016 | 486 Million CHF | 13.55% |
| 2015 | 428 Million CHF | 1.18% |
| 2014 | 423 Million CHF | 67.19% |
| 2013 | 253 Million CHF | -24.48% |
| 2012 | 335 Million CHF | 28.35% |
| 2011 | 261 Million CHF | -30.21% |
| 2010 | 374 Million CHF | 56.49% |
| 2009 | 239 Million CHF | -45.8% |
| 2008 | 441 Million CHF | 8.09% |
| 2007 | 408 Million CHF | 35.55% |
| 2006 | 301 Million CHF | 1.35% |
| 2005 | 297 Million CHF | 40.76% |
| 2004 | 211 Million CHF | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 275.5 Million CHF | 0.0% |
| 2024 Q1 | 275.5 Million CHF | -60.75% |
| 2023 Q2 | 611 Million CHF | 104.35% |
| 2023 Q1 | 299 Million CHF | -66.63% |
| 2023 Q3 | 385.5 Million CHF | -36.91% |
| 2023 FY | 854 Million CHF | -44.58% |
| 2023 Q4 | 702 Million CHF | 82.1% |
| 2022 Q3 | 371 Million CHF | -45.12% |
| 2022 Q4 | 896 Million CHF | 141.51% |
| 2022 FY | 1.54 Billion CHF | 81.08% |
| 2022 Q1 | 322.5 Million CHF | -38.8% |
| 2022 Q2 | 676 Million CHF | 109.61% |
| 2021 Q4 | 527 Million CHF | 328.46% |
| 2021 Q3 | 123 Million CHF | -60.32% |
| 2021 Q2 | 310 Million CHF | 3.33% |
| 2021 Q1 | 300 Million CHF | -9.91% |
| 2021 FY | 851 Million CHF | -5.55% |
| 2020 Q3 | 207.5 Million CHF | -66.21% |
| 2020 FY | 901 Million CHF | -7.3% |
| 2020 Q4 | 333 Million CHF | 60.48% |
| 2020 Q1 | 265 Million CHF | -42.76% |
| 2020 Q2 | 614 Million CHF | 131.7% |
| 2019 Q3 | 227 Million CHF | -9.92% |
| 2019 FY | 972 Million CHF | 15.44% |
| 2019 Q4 | 463 Million CHF | 103.96% |
| 2019 Q1 | 252 Million CHF | -1.75% |
| 2019 Q2 | 252 Million CHF | 0.0% |
| 2018 FY | 842 Million CHF | 16.46% |
| 2018 Q3 | 256.5 Million CHF | 3.22% |
| 2018 Q2 | 248.5 Million CHF | 0.0% |
| 2018 Q1 | 248.5 Million CHF | 20.63% |
| 2018 Q4 | 256.5 Million CHF | 0.0% |
| 2017 FY | 723 Million CHF | 48.77% |
| 2017 Q2 | 183 Million CHF | 0.0% |
| 2017 Q1 | 183 Million CHF | 12.62% |
| 2017 Q3 | 249 Million CHF | 36.07% |
| 2017 Q4 | 206 Million CHF | -17.27% |
| 2016 FY | 486 Million CHF | 13.55% |
| 2016 Q2 | 146 Million CHF | 0.0% |
| 2016 Q1 | 146 Million CHF | -4.58% |
| 2016 Q4 | 162.5 Million CHF | 0.0% |
| 2016 Q3 | 162.5 Million CHF | 11.3% |
| 2015 Q2 | 96 Million CHF | 0.0% |
| 2015 FY | 428 Million CHF | 1.18% |
| 2015 Q3 | 153 Million CHF | 59.38% |
| 2015 Q1 | 96 Million CHF | -16.88% |
| 2015 Q4 | 153 Million CHF | 0.0% |
| 2014 Q2 | 107.5 Million CHF | 0.0% |
| 2014 Q1 | 107.5 Million CHF | -5.7% |
| 2014 FY | 423 Million CHF | 67.19% |
| 2014 Q4 | 115.5 Million CHF | 0.0% |
| 2014 Q3 | 115.5 Million CHF | 7.44% |
| 2013 Q3 | 114 Million CHF | 25.97% |
| 2013 FY | 253 Million CHF | -24.48% |
| 2013 Q1 | 90.5 Million CHF | 0.0% |
| 2013 Q4 | 114 Million CHF | 0.0% |
| 2013 Q2 | 90.5 Million CHF | 0.0% |
| 2012 FY | 335 Million CHF | 28.35% |
| 2011 FY | 261 Million CHF | -30.21% |
| 2010 FY | 374 Million CHF | 56.49% |
| 2009 FY | 239 Million CHF | -45.8% |
| 2008 FY | 441 Million CHF | 8.09% |
| 2007 FY | 408 Million CHF | 35.55% |
| 2006 FY | 301 Million CHF | 1.35% |
| 2005 FY | 297 Million CHF | 40.76% |
| 2004 FY | 211 Million CHF | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| American Bio Medica Corporation | -1.24 Million USD | 70953.462% |
| Arrayit Corporation | -3.62 Million USD | 24392.495% |
| Atlantic International Corp. | -5.73 Million USD | 15451.044% |
| Biocept, Inc. | -31.98 Million USD | 2851.462% |
| Bioqual, Inc. | -19.63 Thousand USD | 4481208.056% |
| CardioGenics Holdings Inc | -772.14 Thousand USD | 114068.674% |
| DermTech, Inc. | -103.73 Million USD | 948.283% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.48 Billion USD | 64.615% |
| HTG Molecular Diagnostics, Inc. | -20.82 Million USD | 4324.758% |
| iMD Companies, Inc. | -175.44 Thousand USD | 501678.833% |
| IDenta Corp. | -1499.00 USD | 58705903.869% |
| Interpace Biosciences, Inc. | 2.8 Million USD | -31283.738% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | -2274389.532% |
| InVitro International | -25.33 Thousand USD | 3473007.376% |
| Lumos Diagnostics Holdings Limited | -7.12 Million USD | 12456.08% |
| Many Bright Ideas Technologies Inc. | -58.11 Thousand USD | 1514417.181% |
| Medical Imaging Corp. | -819.48 Thousand USD | 107485.171% |
| NovelStem International Corp. | -3.52 Million USD | 25058.882% |
| Optigenex Inc. | 1.39 Million USD | -63171.344% |
| PharmChem, Inc. | 973.14 Thousand USD | -90328.27% |
| Proteome Sciences plc | -1.62 Million USD | 54387.477% |
| Response Genetics, Inc | -21.37 Million USD | 4216.574% |
| Rennova Health, Inc. | -1.4 Million USD | 62531.981% |
| RushNet, Inc. | -684.7 Thousand USD | 128622.502% |
| ScreenPro Security Inc. | -2.59 Million USD | 34045.012% |
| Stella Diagnostics Inc. | -11.42 Million USD | 7801.093% |
| StageZero Life Sciences Ltd. | -7.74 Million USD | 11459.586% |
| Todos Medical Ltd. | -9.74 Million USD | 9127.493% |